181 related articles for article (PubMed ID: 22541416)
1. Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab.
Bell MC; Jackson DJ
Ann Allergy Asthma Immunol; 2012 May; 108(5):383-4. PubMed ID: 22541416
[No Abstract] [Full Text] [Related]
2. Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis.
Kibsgaard L; Skjold T; Deleuran M; Vestergaard C
Acta Derm Venereol; 2014 May; 94(3):363-4. PubMed ID: 24162824
[No Abstract] [Full Text] [Related]
3. Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome.
Jagdis A; Vadas P
Ann Allergy Asthma Immunol; 2014 Jul; 113(1):115-6. PubMed ID: 24950847
[No Abstract] [Full Text] [Related]
4. Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome.
da Silva EN; Randall KL
J Allergy Clin Immunol Pract; 2013; 1(6):687-8. PubMed ID: 24565720
[No Abstract] [Full Text] [Related]
5. Successful treatment of mastocytic anaphylactic episodes with reduction of skin mast cells after anti-IgE therapy.
Paraskevopoulos G; Sifnaios E; Christodoulopoulos K; Mantopoulou F; Papakonstantis M; Sabaziotis D
Eur Ann Allergy Clin Immunol; 2013 Apr; 45(2):52-5. PubMed ID: 23821833
[TBL] [Abstract][Full Text] [Related]
6. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis.
Carter MC; Robyn JA; Bressler PB; Walker JC; Shapiro GG; Metcalfe DD
J Allergy Clin Immunol; 2007 Jun; 119(6):1550-1. PubMed ID: 17481708
[No Abstract] [Full Text] [Related]
7. Use of omalizumab in the treatment of food allergy and anaphylaxis.
Lieberman JA; Chehade M
Curr Allergy Asthma Rep; 2013 Feb; 13(1):78-84. PubMed ID: 23065311
[TBL] [Abstract][Full Text] [Related]
8. Omalizumab monotherapy for bee sting and unprovoked "anaphylaxis" in a patient with systemic mastocytosis and undetectable specific IgE.
Kontou-Fili K; Filis CI; Voulgari C; Panayiotidis PG
Ann Allergy Asthma Immunol; 2010 Jun; 104(6):537-9. PubMed ID: 20568389
[No Abstract] [Full Text] [Related]
9. Omalizumab treatment of systemic mast cell activation disease: experiences from four cases.
Molderings GJ; Raithel M; Kratz F; Azemar M; Haenisch B; Harzer S; Homann J
Intern Med; 2011; 50(6):611-5. PubMed ID: 21422688
[TBL] [Abstract][Full Text] [Related]
10. Treatment with a combination of omalizumab and specific immunotherapy for severe anaphylaxis after a wasp sting.
Palgan K; Bartuzi Z; Gotz-Zbikowska M
Int J Immunopathol Pharmacol; 2014; 27(1):109-12. PubMed ID: 24674685
[TBL] [Abstract][Full Text] [Related]
11. Anaphylaxis to vapors of roasting chicken controlled by omalizumab.
Barnig C; Hilger C; Muti D; Blaumeiser M; Purohit A; Hentges F; de Blay F
J Investig Allergol Clin Immunol; 2012; 22(6):439-40. PubMed ID: 23101190
[No Abstract] [Full Text] [Related]
12. The urticarias: pathophysiology and management.
Grattan C
Clin Med (Lond); 2012 Apr; 12(2):164-7. PubMed ID: 22586795
[No Abstract] [Full Text] [Related]
13. [Dermatological implications of omalizumab, an anti-IgE antibody].
Di Lucca-Chrisment J
Rev Med Suisse; 2015 Apr; 11(468):779-80, 782-3. PubMed ID: 26021140
[TBL] [Abstract][Full Text] [Related]
14. Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient.
Douglass JA; Carroll K; Voskamp A; Bourke P; Wei A; O'Hehir RE
Allergy; 2010 Jul; 65(7):926-7. PubMed ID: 19889117
[No Abstract] [Full Text] [Related]
15. Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis.
Matito A; Blázquez-Goñi C; Morgado JM; Alvarez-Twose I; Mollejo M; Sánchez-Muñoz L; Escribano L
Ann Allergy Asthma Immunol; 2013 Nov; 111(5):425-6. PubMed ID: 24125156
[No Abstract] [Full Text] [Related]
16. Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report.
Sokol KC; Ghazi A; Kelly BC; Grant JA
J Allergy Clin Immunol Pract; 2014; 2(3):266-70. PubMed ID: 24811015
[TBL] [Abstract][Full Text] [Related]
17. Omalizumab in children.
Licari A; Marseglia A; Caimmi S; Castagnoli R; Foiadelli T; Barberi S; Marseglia GL
Paediatr Drugs; 2014 Dec; 16(6):491-502. PubMed ID: 25404353
[TBL] [Abstract][Full Text] [Related]
18. Omalizumab and hypersensitivity reactions.
Shankar T; Petrov AA
Curr Opin Allergy Clin Immunol; 2013 Feb; 13(1):19-24. PubMed ID: 23242113
[TBL] [Abstract][Full Text] [Related]
19. Unpredicted adverse reaction to omalizumab.
Jandus P; Hausmann O; Haeberli G; Gentinetta T; Mueller U; Helbling A
J Investig Allergol Clin Immunol; 2011; 21(7):563-6. PubMed ID: 22312942
[TBL] [Abstract][Full Text] [Related]
20. Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab.
de Klerk TA; Sharma V; Arkwright PD; Biswas S
J AAPOS; 2013 Jun; 17(3):305-6. PubMed ID: 23607979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
